Ionis Pharmaceuticals
IONS
310 hedge funds and large institutions have $6.35B invested in Ionis Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 102 increasing their positions, 103 reducing their positions, and 27 closing their positions.
41% more call options, than puts
Call options by funds: $29.2M | Put options by funds: $20.7M
41% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 27
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more capital invested
Capital invested by funds: $5.6B → $6.35B (+$744M)
2.06% more ownership
Funds ownership: 95.43% → 97.49% (+2.1%)
2% more funds holding
Funds holding: 304 → 310 (+6)
1% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 103
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$59.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$47.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$44M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$29.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$40.5M |
| 2 |
Swedbank
Stockholm,
Sweden
|
-$33M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$30M |
| 4 |
ClearBridge Investments
New York
|
-$14.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$10.3M |
IONS Hedge Fund Activity: Q3 2023 in Review
310 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2023, worth a combined $6.35B — up 13% from $5.6B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IONS positions and 27 closed out — a net gain of 11 holders — while 102 added to existing stakes and 103 trimmed.
The largest buyer was Macquarie Group, adding an estimated $59.3M. The largest seller was Thrivent Financial for Lutherans, exiting entirely with an estimated $40.5M sold.
- 310 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2023, up from 304 in Q2 2023.
- Funds reported $6.35B of Ionis Pharmaceuticals stock for Q3 2023, up 13% quarter-over-quarter.
- 38 funds opened new Ionis Pharmaceuticals positions in Q3 2023 and 27 closed out, a net change of +11 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2023 was Macquarie Group, an estimated $59.3M added.
- The largest Ionis Pharmaceuticals seller in Q3 2023 was Thrivent Financial for Lutherans, an estimated $40.5M sold.
Based on aggregated 13F filings for Q3 2023.